DE60015831D1 - Thyromimetika als Mittel gegen Fettleibigkeit - Google Patents
Thyromimetika als Mittel gegen FettleibigkeitInfo
- Publication number
- DE60015831D1 DE60015831D1 DE60015831T DE60015831T DE60015831D1 DE 60015831 D1 DE60015831 D1 DE 60015831D1 DE 60015831 T DE60015831 T DE 60015831T DE 60015831 T DE60015831 T DE 60015831T DE 60015831 D1 DE60015831 D1 DE 60015831D1
- Authority
- DE
- Germany
- Prior art keywords
- lower alkyl
- hydrogen
- cycloalkyl
- aryl
- hydroxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000883 anti-obesity agent Substances 0.000 title 1
- 229940125710 antiobesity agent Drugs 0.000 title 1
- 230000000929 thyromimetic effect Effects 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 11
- 229910052739 hydrogen Inorganic materials 0.000 abstract 5
- 239000001257 hydrogen Substances 0.000 abstract 5
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 4
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 150000002367 halogens Chemical class 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 3
- 208000008589 Obesity Diseases 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 150000001721 carbon Chemical group 0.000 abstract 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 150000002431 hydrogen Chemical group 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 235000020824 obesity Nutrition 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 229910052717 sulfur Inorganic materials 0.000 abstract 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 125000004423 acyloxy group Chemical group 0.000 abstract 1
- 150000001408 amides Chemical class 0.000 abstract 1
- 229940125709 anorectic agent Drugs 0.000 abstract 1
- 239000002830 appetite depressant Substances 0.000 abstract 1
- 125000002837 carbocyclic group Chemical group 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Valve Device For Special Equipments (AREA)
- Refinement Of Pig-Iron, Manufacture Of Cast Iron, And Steel Manufacture Other Than In Revolving Furnaces (AREA)
- Discharging, Photosensitive Material Shape In Electrophotography (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Processes Of Treating Macromolecular Substances (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12201599P | 1999-03-01 | 1999-03-01 | |
US122015P | 1999-03-01 |
Publications (2)
Publication Number | Publication Date |
---|---|
DE60015831D1 true DE60015831D1 (de) | 2004-12-23 |
DE60015831T2 DE60015831T2 (de) | 2005-12-15 |
Family
ID=22400061
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60015831T Expired - Fee Related DE60015831T2 (de) | 1999-03-01 | 2000-02-03 | Thyromimetika als Mittel gegen Fettleibigkeit |
Country Status (15)
Country | Link |
---|---|
US (2) | US6344481B1 (de) |
EP (1) | EP1036564B1 (de) |
JP (1) | JP2000256190A (de) |
KR (1) | KR100368354B1 (de) |
AT (1) | ATE282410T1 (de) |
AU (1) | AU1635300A (de) |
CA (1) | CA2299972C (de) |
CO (1) | CO5150235A1 (de) |
DE (1) | DE60015831T2 (de) |
ES (1) | ES2233282T3 (de) |
HU (1) | HUP0000921A3 (de) |
IL (1) | IL134382A0 (de) |
NZ (1) | NZ503122A (de) |
PE (1) | PE20001539A1 (de) |
ZA (1) | ZA200001000B (de) |
Families Citing this family (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6716810B1 (en) * | 1998-12-09 | 2004-04-06 | Eleanor Roosevelt Institute | Composition and method for regulation of body weight and associated conditions |
US6344481B1 (en) * | 1999-03-01 | 2002-02-05 | Pfizer Inc. | Thyromimetic antiobesity agents |
US20030008838A1 (en) * | 2001-04-03 | 2003-01-09 | Havel Peter J. | Method of increasing endogenous leptin production |
US20070203225A1 (en) * | 2001-04-03 | 2007-08-30 | Havel Peter J | Method of increasing endogenous adiponectin production and leptin production |
WO2003077847A2 (en) * | 2002-03-12 | 2003-09-25 | Merck & Co., Inc. | Substituted amides |
US6825209B2 (en) | 2002-04-15 | 2004-11-30 | Research Triangle Institute | Compounds having unique CB1 receptor binding selectivity and methods for their production and use |
US7105526B2 (en) | 2002-06-28 | 2006-09-12 | Banyu Pharmaceuticals Co., Ltd. | Benzimidazole derivatives |
EP1556373A1 (de) * | 2002-10-18 | 2005-07-27 | Pfizer Products Inc. | Cannabinoid rezeptorenliganden und ihre verwendung |
US20040122033A1 (en) * | 2002-12-10 | 2004-06-24 | Nargund Ravi P. | Combination therapy for the treatment of obesity |
US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
ATE547404T1 (de) | 2003-09-22 | 2012-03-15 | Msd Kk | Piperidinderivate |
US7829552B2 (en) * | 2003-11-19 | 2010-11-09 | Metabasis Therapeutics, Inc. | Phosphorus-containing thyromimetics |
EP1730310A2 (de) * | 2004-03-22 | 2006-12-13 | The Regents Of The University Of California | Formulierung zur steigerung der endogenen adiponectin- und leptinproduktion |
US20080125403A1 (en) | 2004-04-02 | 2008-05-29 | Merck & Co., Inc. | Method of Treating Men with Metabolic and Anthropometric Disorders |
MX2007014502A (es) | 2005-05-26 | 2008-02-07 | Metabasis Therapeutics Inc | Tiromimeticos para el tratamiento de enfermedades del higado graso. |
EP1890768A2 (de) * | 2005-05-26 | 2008-02-27 | Metabasis Therapeutics, Inc. | Neue phosphinsäurehaltige thyromimetika |
US8138206B2 (en) | 2005-05-30 | 2012-03-20 | Msd. K.K. | Piperidine derivative |
WO2007018248A1 (ja) | 2005-08-10 | 2007-02-15 | Banyu Pharmaceutical Co., Ltd. | ピリドン化合物 |
US7875633B2 (en) | 2005-08-24 | 2011-01-25 | Banyu Pharmaceutical Co., Ltd. | Phenylpyridone derivative |
WO2007029847A1 (ja) | 2005-09-07 | 2007-03-15 | Banyu Pharmaceutical Co., Ltd. | 二環性芳香族置換ピリドン誘導体 |
JP4879988B2 (ja) | 2005-09-29 | 2012-02-22 | メルク・シャープ・エンド・ドーム・コーポレイション | メラノコルチン−4受容体モジュレーターとしてのアシル化スピロピペリジン誘導体 |
RU2008119687A (ru) | 2005-10-21 | 2009-11-27 | Новартис АГ (CH) | Комбинации органических соединений |
WO2007049798A1 (ja) | 2005-10-27 | 2007-05-03 | Banyu Pharmaceutical Co., Ltd. | 新規ベンゾオキサチイン誘導体 |
AU2006312557B2 (en) | 2005-11-10 | 2011-12-08 | Msd K.K. | Aza-substituted spiro derivative |
WO2007132475A1 (en) * | 2006-05-15 | 2007-11-22 | Cadila Healthcare Limited | Selective tr-beta 1 agonist |
EP2946778A1 (de) | 2006-09-22 | 2015-11-25 | Merck Sharp & Dohme Corp. | Behandlungsverfahren mit verwendung von fettsäuresyntheseinhibitoren |
AU2007301126A1 (en) | 2006-09-28 | 2008-04-03 | Banyu Pharmaceutical Co., Ltd. | Diaryl ketimine derivative |
JP5319518B2 (ja) | 2007-04-02 | 2013-10-16 | Msd株式会社 | インドールジオン誘導体 |
WO2008151257A2 (en) | 2007-06-04 | 2008-12-11 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
US20110015181A1 (en) | 2008-03-06 | 2011-01-20 | Makoto Ando | Alkylaminopyridine derivative |
US20110015198A1 (en) | 2008-03-28 | 2011-01-20 | Banyu Pharmaceutical Co., Inc. | Diarylmethylamide derivative having melanin-concentrating hormone receptor antagonism |
EP2328910B1 (de) | 2008-06-04 | 2014-08-06 | Synergy Pharmaceuticals Inc. | Für die behandlung von gastrointestinalen erkrankungen, entzündungen, krebs und anderen erkrankungen geeignete agonisten von guanylatcyclase |
CA2727914A1 (en) | 2008-06-19 | 2009-12-23 | Banyu Pharmaceutical Co., Ltd. | Spirodiamine-diaryl ketoxime derivative technical field |
AU2009270833B2 (en) | 2008-07-16 | 2015-02-19 | Bausch Health Ireland Limited | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
AU2009277736A1 (en) | 2008-07-30 | 2010-02-04 | Banyu Pharmaceutical Co., Ltd. | (5-membered)-(5-membered) or (5-membered)-(6-membered) fused ring cycloalkylamine derivative |
CA2741125A1 (en) | 2008-10-22 | 2010-04-29 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
AU2009309229B2 (en) | 2008-10-27 | 2012-03-15 | Cadila Healthcare Limited | Thyroid receptor ligands |
WO2010051206A1 (en) | 2008-10-31 | 2010-05-06 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
WO2010086878A2 (en) | 2009-01-09 | 2010-08-05 | Cadila Healthcare Limited | Thyroid receptor modulators |
KR101396606B1 (ko) | 2009-04-20 | 2014-05-16 | 미쓰비시 타나베 파마 코퍼레이션 | 신규 갑상선 호르몬 β 수용체 작동약 |
CA2786314A1 (en) | 2010-02-25 | 2011-09-01 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
US9401828B2 (en) | 2010-05-20 | 2016-07-26 | Kandou Labs, S.A. | Methods and systems for low-power and pin-efficient communications with superposition signaling codes |
WO2012027331A1 (en) | 2010-08-27 | 2012-03-01 | Ironwood Pharmaceuticals, Inc. | Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders |
US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
PE20140859A1 (es) | 2011-02-25 | 2014-07-25 | Merck Sharp & Dohme | Novedosos derivados de azabencimidazol ciclico utiles como agentes antidiabeticos |
CA3100941C (en) | 2011-03-01 | 2024-03-05 | Synergy Pharmaceuticals Inc. | Process of preparing guanylate cyclase c agonists |
BR112015002080A2 (pt) | 2012-08-02 | 2017-07-04 | Merck Sharp & Dohme | composto, composição farmacêutica, uso de um composto, e, método de tratamento ou de prevenção de um transtorno, de uma condição ou de uma doença |
EP2958562A4 (de) | 2013-02-22 | 2016-08-10 | Merck Sharp & Dohme | Antidiabetische bicyclische verbindungen |
US9650375B2 (en) | 2013-03-14 | 2017-05-16 | Merck Sharp & Dohme Corp. | Indole derivatives useful as anti-diabetic agents |
EP2968439A2 (de) | 2013-03-15 | 2016-01-20 | Synergy Pharmaceuticals Inc. | Zusammensetzungen zur behandlung von magen-darm-störungen |
CA2905438A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
US10011637B2 (en) | 2013-06-05 | 2018-07-03 | Synergy Pharmaceuticals, Inc. | Ultra-pure agonists of guanylate cyclase C, method of making and using same |
WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
BR112017003745A2 (pt) | 2014-08-29 | 2017-12-05 | Tes Pharma S R L | inibidores de semialdeído descarboxilase de ácido alfa-amino-beta-carboximucônico |
TWI767945B (zh) | 2016-10-14 | 2022-06-21 | 義大利商Tes製藥(股份)責任有限公司 | α-胺基-β-羧基己二烯二酸半醛去羧酶之抑制劑 |
EP3541395A4 (de) | 2016-11-21 | 2020-07-01 | Viking Therapeutics, Inc. | Verfahren zur behandlung einer glykogenspeicherkrankheit |
EP3551176A4 (de) | 2016-12-06 | 2020-06-24 | Merck Sharp & Dohme Corp. | Antidiabetische heterocyclische verbindungen |
WO2018118670A1 (en) | 2016-12-20 | 2018-06-28 | Merck Sharp & Dohme Corp. | Antidiabetic spirochroman compounds |
US11707472B2 (en) | 2017-06-05 | 2023-07-25 | Viking Therapeutics, Inc. | Compositions for the treatment of fibrosis |
CN111094554A (zh) | 2017-09-14 | 2020-05-01 | 国立研究开发法人理化学研究所 | 视网膜组织的制备方法 |
CN112135832A (zh) | 2018-03-22 | 2020-12-25 | 维京治疗公司 | 化合物的晶型和制备化合物的晶型的方法 |
SG11202104550WA (en) | 2018-11-20 | 2021-05-28 | Tes Pharma S R L | INHIBITORS OF a-AMINO-ß-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE |
KR20210138639A (ko) | 2019-03-13 | 2021-11-19 | 다이니뽄 스미토모 세이야쿠 가부시키가이샤 | 이식용 신경 망막의 품질을 평가하는 방법 및 이식용 신경 망막 시트 |
WO2022054924A1 (ja) | 2020-09-11 | 2022-03-17 | 大日本住友製薬株式会社 | 移植用組織のための媒体 |
WO2022054925A1 (ja) | 2020-09-11 | 2022-03-17 | 国立研究開発法人理化学研究所 | 神経網膜を含む細胞凝集体とマトリクスとを含む複合体及びその製造方法 |
WO2023090427A1 (ja) | 2021-11-19 | 2023-05-25 | 国立研究開発法人理化学研究所 | シート状網膜組織の製造方法 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5315739B2 (de) * | 1973-10-30 | 1978-05-26 | ||
JPS50124993A (de) * | 1974-03-20 | 1975-10-01 | ||
JPS5937018B2 (ja) * | 1978-06-16 | 1984-09-07 | 株式会社トクヤマ | 難燃化ポリプロピレン組成物 |
ZA824382B (en) | 1981-07-07 | 1984-02-29 | Wyeth John & Brother Ltd | Anti-obesity agents |
GB8501372D0 (en) * | 1985-01-18 | 1985-02-20 | Smith Kline French Lab | Chemical compounds |
GB8519154D0 (en) | 1985-07-30 | 1985-09-04 | Ici Plc | Aromatic ethers |
GB8714901D0 (en) | 1986-07-23 | 1987-07-29 | Ici Plc | Amide derivatives |
GB8801306D0 (en) | 1988-01-21 | 1988-02-17 | Ici Plc | Chemical compounds |
ATE159515T1 (de) * | 1992-07-21 | 1997-11-15 | Ciba Geigy Ag | Oxamidsäure-derivate als hypocholesterämische mittel |
JPH0834976A (ja) * | 1994-07-25 | 1996-02-06 | Asahi Denka Kogyo Kk | 潜熱利用型蓄熱材 |
AU5524896A (en) * | 1995-03-20 | 1996-10-08 | Institut Pasteur De Lille | Modulators of ob gene and screening methods therefor |
EP0920864A1 (de) * | 1997-12-03 | 1999-06-09 | Pfizer Products Inc. | Kombinationstherapie durch einen spezifischen beta-3 Agonisten und einen Appetithemmer |
CA2363145C (en) * | 1999-03-01 | 2006-02-14 | Pfizer Products Inc. | Oxamic acids and derivatives as thyroid receptor ligands |
US6344481B1 (en) * | 1999-03-01 | 2002-02-05 | Pfizer Inc. | Thyromimetic antiobesity agents |
-
2000
- 2000-01-20 US US09/488,110 patent/US6344481B1/en not_active Expired - Fee Related
- 2000-02-03 DE DE60015831T patent/DE60015831T2/de not_active Expired - Fee Related
- 2000-02-03 IL IL13438200A patent/IL134382A0/xx unknown
- 2000-02-03 EP EP00300830A patent/EP1036564B1/de not_active Expired - Lifetime
- 2000-02-03 ES ES00300830T patent/ES2233282T3/es not_active Expired - Lifetime
- 2000-02-03 AT AT00300830T patent/ATE282410T1/de not_active IP Right Cessation
- 2000-02-11 AU AU16353/00A patent/AU1635300A/en not_active Abandoned
- 2000-02-25 JP JP2000049507A patent/JP2000256190A/ja active Pending
- 2000-02-28 HU HU0000921A patent/HUP0000921A3/hu unknown
- 2000-02-28 KR KR10-2000-0009860A patent/KR100368354B1/ko not_active IP Right Cessation
- 2000-02-28 PE PE2000000162A patent/PE20001539A1/es not_active Application Discontinuation
- 2000-02-29 CA CA002299972A patent/CA2299972C/en not_active Expired - Fee Related
- 2000-02-29 ZA ZA200001000A patent/ZA200001000B/xx unknown
- 2000-02-29 NZ NZ503122A patent/NZ503122A/en unknown
- 2000-03-01 CO CO00014834A patent/CO5150235A1/es unknown
-
2001
- 2001-10-16 US US09/978,980 patent/US6555578B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
KR20010006712A (ko) | 2001-01-26 |
HUP0000921A2 (hu) | 2000-12-28 |
AU1635300A (en) | 2000-09-07 |
HU0000921D0 (en) | 2000-04-28 |
ZA200001000B (en) | 2001-08-29 |
IL134382A0 (en) | 2001-04-30 |
US20020035153A1 (en) | 2002-03-21 |
DE60015831T2 (de) | 2005-12-15 |
KR100368354B1 (ko) | 2003-01-24 |
US6555578B2 (en) | 2003-04-29 |
CO5150235A1 (es) | 2002-04-29 |
CA2299972A1 (en) | 2000-09-01 |
NZ503122A (en) | 2001-11-30 |
PE20001539A1 (es) | 2001-01-08 |
EP1036564A1 (de) | 2000-09-20 |
CA2299972C (en) | 2003-08-19 |
EP1036564B1 (de) | 2004-11-17 |
ATE282410T1 (de) | 2004-12-15 |
JP2000256190A (ja) | 2000-09-19 |
ES2233282T3 (es) | 2005-06-16 |
HUP0000921A3 (en) | 2004-06-28 |
US6344481B1 (en) | 2002-02-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60015831D1 (de) | Thyromimetika als Mittel gegen Fettleibigkeit | |
DE69706660D1 (de) | N-aminoalkyldibenzofuran-carboxamide als dopaminrezeptor-subtyp spezifische liganden | |
ATE375341T1 (de) | Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen | |
DE69229442D1 (de) | Substituierte dibenzooxazepin-verbindungen, pharmazeutische zusammensetzungen und verfahren zur verwendung | |
RU2005105576A (ru) | Производные плевромутилина в качестве противомикроюных средств | |
DE60014916D1 (de) | Die Verwendung eines Benzimidazoles zur Herstellung eines Medikamentes zur Krebsvorbeugung | |
KR890005031A (ko) | L-도파유도체 또는 그의 산부가염, 그의 제조방법 및 그의 용도 | |
ATE250054T1 (de) | Oxazolidinone derivate und pharmazeutische zusammensetzungen | |
KR890011596A (ko) | 불면증 치료용 의약품의 제조에 있어서 1,4-이치환-피페리디닐 화합물의 용도 | |
AU2342397A (en) | N-aminoalkyldibenzothiophenecarboxamides; dopamine receptor subtype specific ligands | |
DE69707372T2 (de) | Verwendung eines Phosphorsäurediesters zur Herstellung eines Arzneimittels zur Behandlung von Akne | |
DE68918991T2 (de) | Anwendung von Vanillin-Derivaten zur Herstellung eines Arzneimittels zur Behandlung von Herpes simplex-Infektion. | |
ATE284684T1 (de) | Amidderivate zur behandlung neurodegenerativer erkrankungen der netzhaut | |
BR0317263A (pt) | Ligantes alfa2delta para o tratamento de fibromialgia e outras perturbações | |
ATE262330T1 (de) | Verwendung eines nitroxids oder seiner prodrugs zur prophylaktischen und therapeutischen behandlung von krebs | |
DE69518706D1 (de) | Verwendung von Diphenylethanderivaten zur Herstellung eines Arzneimittels zur Behandlung von Glaukom | |
NZ293691A (en) | Use of a medicament containing an anilide compound for treatment of type i allergic diseases | |
SE0104333D0 (sv) | Therapeutic agents | |
DE60123528D1 (de) | Verwendung eines Mittels zur Verbesserung der Astrozytenfunktion zur Behandlung von Parkinsons Krankheit | |
DE69315363D1 (de) | Amphotere tricyclische Verbindungen als antihistaminische und antiallergische Mittel | |
ATE181503T1 (de) | Verwendung von idazoxan und derivaten zur herstellung eines arzneimittels zur behandlung von parkinsonismus und seiner evolution | |
BR9708922A (pt) | Piridil-e pirimidil-piperazinas no tratamento de doenças causadas por substâncias usadas em excesso | |
DE60005525D1 (de) | 2-aminotetraline zur behandlung von glaukom | |
FR2869316A1 (fr) | Derives de pyridoindolone substitues en -6, leur preparation et leur application en therapeutique. | |
BR0008543A (pt) | Agente terapêutico para a claudicação intermitente, e, uso de um derivado de piperidina ou de um sal deste farmaceuticamente aceitável |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8339 | Ceased/non-payment of the annual fee |